Tempest Therapeutics Inc (TPST) - Total Assets
Based on the latest financial reports, Tempest Therapeutics Inc (TPST) holds total assets worth $10.75 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Tempest Therapeutics Inc (TPST) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Tempest Therapeutics Inc - Total Assets Trend (2011–2025)
This chart illustrates how Tempest Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. See shareholders equity of Tempest Therapeutics Inc for net asset value and shareholders' equity analysis.
Tempest Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Tempest Therapeutics Inc's total assets of $10.75 Million consist of 48.8% current assets and 51.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 45.5% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2011–2025)
This chart illustrates how Tempest Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Tempest Therapeutics Inc market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Tempest Therapeutics Inc's current assets represent 48.8% of total assets in 2025, a decrease from 100.0% in 2011.
- Cash Position: Cash and equivalents constituted 45.5% of total assets in 2025, down from 99.0% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2011.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Tempest Therapeutics Inc Competitors by Total Assets
Key competitors of Tempest Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
ALTEOGEN Inc
KQ:196170
|
Korea | ₩729.47 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $440.10 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Galapagos N.V.
AS:GLPG
|
Netherlands | €3.37 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
Tempest Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.74 | 1.70 | 7.20 |
| Quick Ratio | 0.74 | 1.70 | 7.09 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-865.00K | $9.26 Million | $60.70 Million |
Tempest Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Tempest Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 22.61 |
| Latest Market Cap to Assets Ratio | 0.75 |
| Asset Growth Rate (YoY) | -59.2% |
| Total Assets | $16.93 Million |
| Market Capitalization | $12.67 Million USD |
Valuation Analysis
Below Book Valuation: The market values Tempest Therapeutics Inc's assets below their book value (0.75x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Tempest Therapeutics Inc's assets decreased by 59.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Tempest Therapeutics Inc (2011–2025)
The table below shows the annual total assets of Tempest Therapeutics Inc from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $16.93 Million | -59.19% |
| 2024-12-31 | $41.49 Million | -19.60% |
| 2023-12-31 | $51.60 Million | +11.96% |
| 2022-12-31 | $46.09 Million | -37.07% |
| 2021-12-31 | $73.24 Million | +220.33% |
| 2020-12-31 | $22.86 Million | -69.50% |
| 2019-12-31 | $74.97 Million | -10.83% |
| 2018-12-31 | $84.07 Million | +324.36% |
| 2017-12-31 | $19.81 Million | -83.83% |
| 2016-12-31 | $122.54 Million | -11.59% |
| 2015-12-31 | $138.61 Million | +111.39% |
| 2014-12-31 | $65.57 Million | +37.92% |
| 2013-12-31 | $47.55 Million | +44.89% |
| 2012-12-31 | $32.81 Million | +615.68% |
| 2011-12-31 | $4.58 Million | -- |
About Tempest Therapeutics Inc
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-14… Read more